Protagenic Therapeutics, Inc., a New York-based biopharmaceutical company, announced its focus on the discovery and development of therapeutics aimed at treating neuropsychiatric and mood disorders related to stress. With its lead compound, PT00114, the company has produced a synthetic version of teneurin carboxy-terminal associated peptide, a brain signaling peptide that can curb overactive stress responses. Protagenic Therapeutics, Inc. is dedicated to leveraging scientific research to improve the lives of those affected by stress-related disorders.
Protagenic Therapeutics, Inc.'s ticker is PTIX
The company's shares trade on the OTC stock exchange
They are based in New York City, New York
There are 1-10 employees working at Protagenic Therapeutics, Inc.
It is http://protagenic.com/
Protagenic Therapeutics, Inc. is in the Technology sector
Protagenic Therapeutics, Inc. is in the Networking & Communication Devices industry
The following five companies are Protagenic Therapeutics, Inc.'s industry peers: